Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029

  • Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for pandemic preparedness.
  • The five-year contract allows for the production of up to 80 million doses at short notice until 2029, CureVac said, adding that those doses could be for the remainder of the current pandemic or future outbreaks.
  • CureVac gave up on its first-generation COVID-19 vaccine candidate, CVnCoV, last year after poor data, but trials for the next-generation COVID-19 shots have begun.
  • Related: CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial.
  • Under the contract, the federal government will pay CureVac and GSK an annual standby fee after completing the setup period, which requires the companies to maintain manufacturing capacity at constant readiness. 
  • Price Action: CVAC shares are down 2.66% at $17.22, and GSK stock is down 0.40% at $46.46 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.